Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Accolate captures 3.4% of new asthma controller scripts; Zeneca Zoladex sales gain 57%.

Executive Summary

ZENECA ACCOLATE GARNERS 3.4% OF ASTHMA CONTROLLER NEW RXs BY JANUARY, three months after its October launch, according to Scott Levin's Rx Watch. In January, "Accolate captured nearly 4% of the new retail dollars," Scott-Levin stated. "Its share has steadily increased since it was launched." Scott-Levin calculated that Accolate produced 41,000 new prescriptions in January, generating $2.2 mil. retail dollars. Primary care physicians wrote 50% of January Accolate prescriptions, followed by pulmonary disease specialists, with 22% of scripts, and allergists, with 16%. The agent's share among pulmonary and allergy specialists was "considerably higher than its 3.4% share overall," Scott-Levin commented.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029893

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel